UB Paderborn / Katalog / Suche / in CDI

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Nature Medicine, 2021-05

2021

Volltextzugriff (PDF)

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France

Multiple sclerosis, 2020-01, Vol.26 (1), p.118-122

2020

Volltextzugriff (PDF)

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Annals of neurology, 2023-06, Vol.93 (6), p.1053-1068

2023

Volltextzugriff (PDF)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis

PloS one, 2017-01, Vol.12 (1), p.e0168834-e0168834

2017

Volltextzugriff (PDF)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease

Journal of neurology, neurosurgery and psychiatry, 2017-02, Vol.88 (2), p.132

2017

Volltextzugriff (PDF)

Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses

Environmental research, 2018-05, Vol.163, p.43-52

2018

Volltextzugriff (PDF)

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study

PloS one, 2015-07, Vol.10 (7), p.e0132033-e0132033

2015

Volltextzugriff (PDF)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

Frontiers in immunology, 2023, Vol.14, p.1004795-1004795

2023

Volltextzugriff (PDF)

The effect of oxysterols on nerve impulses

Biochimie, 2018-10, Vol.153, p.46-51

2018

Volltextzugriff (PDF)

False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients

Multiple sclerosis, 2016-08, Vol.22 (9), p.1231-1234

2016

Volltextzugriff (PDF)

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study

Frontiers in neurology, 2024-01, Vol.14, p.1303874-1303874

2024

Volltextzugriff (PDF)

Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera

International journal of molecular sciences, 2022-03, Vol.23 (5), p.2791

2022

Volltextzugriff (PDF)

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

Journal of neurology, 2016-01, Vol.263 (1), p.140-149

2016

Volltextzugriff (PDF)

Modulation of Kv3.1b potassium channel level and intracellular potassium concentration in 158N murine oligodendrocytes and BV-2 murine microglial cells treated with 7-ketocholesterol, 24S-hydroxycholesterol or tetracosanoic acid (C24:0)

Biochimie, 2018-10, Vol.153, p.56-69

2018

Volltextzugriff (PDF)

Microglial Cell Morphology and Phagocytic Activity Are Critically Regulated by the Neurosteroid Allopregnanolone: A Possible Role in Neuroprotection

Cells (Basel, Switzerland), 2021-03, Vol.10 (3), p.698

2021

Volltextzugriff (PDF)

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

Journal of neurology, 2012-11, Vol.259 (11), p.2293-2298

2012

Volltextzugriff (PDF)

Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors

Viruses, 2020-12, Vol.12 (12), p.1380

2020

Volltextzugriff (PDF)

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

The New England journal of medicine, 2017-01, Vol.376 (3), p.209-220

2017

Volltextzugriff (PDF)

NMO-IgG and Devic's neuromyelitis optica: a French experience

Multiple sclerosis, 2008-05, Vol.14 (4), p.440-445

2008

Volltextzugriff (PDF)

NMO-lgG and Devic's neuromyelitis optica : a French experience

Multiple sclerosis, 2008-05, Vol.14 (4), p.440-445

2008

Volltextzugriff (PDF)

The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Multiple sclerosis and related disorders, 2021-08, Vol.53, p.103012-103012, Article 103012

2021

Volltextzugriff (PDF)

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Multiple sclerosis, 2023-02, Vol.29 (2), p.236-247

2023

Volltextzugriff (PDF)

Emotional experience is increased and emotion recognition decreased in multiple sclerosis

Scientific reports, 2021-11, Vol.11 (1), p.21885-21885, Article 21885

2021

Volltextzugriff (PDF)

Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy

Brain (London, England : 1878), 2012-10, Vol.135 (Pt 10), p.2980-2993

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease

Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

The effect of oxysterols on nerve impulses

False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study

Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

Modulation of Kv3.1b potassium channel level and intracellular potassium concentration in 158N murine oligodendrocytes and BV-2 murine microglial cells treated with 7-ketocholesterol, 24S-hydroxycholesterol or tetracosanoic acid (C24:0)

Microglial Cell Morphology and Phagocytic Activity Are Critically Regulated by the Neurosteroid Allopregnanolone: A Possible Role in Neuroprotection

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

NMO-IgG and Devic's neuromyelitis optica: a French experience

NMO-lgG and Devic's neuromyelitis optica : a French experience

The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

Emotional experience is increased and emotion recognition decreased in multiple sclerosis

Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy

Suchergebnisse filtern